{"id":"W2950604500","doi":"10.1097/01.hs9.0000562556.40615.f8","title":"PS1065 OPEN‐LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3‐MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Cohort; Chemotherapy; Surgery; Internal medicine; Gastroenterology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008589805,0.0005957421,0.001795058,0.0001228828,0.0001340088,0.00009984622,0.0009944889,0.0002841626,0.0008830403],"category_scores_gemma":[0.00229671,0.0004162451,0.0001476335,0.0009850125,0.0002207259,0.0002954663,0.000622676,0.0005192738,0.00008410071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003428426,"about_ca_system_score_gemma":0.002969879,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01438468,"about_ca_topic_score_gemma":0.003860988,"domain_scores_codex":[0.9947118,0.0002619227,0.001792114,0.001249893,0.001029296,0.0009550298],"domain_scores_gemma":[0.9939775,0.00218311,0.0005043127,0.001659633,0.001392438,0.000282936],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4418584,0.02854323,0.3394673,0.002738101,0.00492147,0.002911489,0.03695987,0.0005647657,0.02028933,0.0001654964,0.09262355,0.02895693],"study_design_scores_gemma":[0.8305521,0.009553534,0.09938964,0.00304881,0.0003540062,0.0000964033,0.0250269,0.01158951,0.01295823,0.0001129546,0.006204846,0.00111304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822831,0.0001622157,0.00003655565,0.0009500248,0.0002883555,0.01318655,0.001166187,0.00008056992,0.001846405],"genre_scores_gemma":[0.9921712,0.0002452114,0.00107349,0.001478842,0.0002120933,0.0007244993,0.001512664,0.0001691597,0.002412821],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3886937,"threshold_uncertainty_score":0.9998289,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04942912092761675,"score_gpt":0.3420307488687258,"score_spread":0.292601627941109,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}